Epidemiology of metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis and associated cardiometabolic factors in adults in China (2013-2023): A systematic review and meta-analysis

Figure 1 PRISMA flow diagram for article selection for the meta-analysis. MASLD: Metabolic dysfunction-associated steatotic liver disease.

Figure 2 Forest plot of the prevalence of metabolic dysfunction-associated steatohepatitis and the annual incidence of metabolic dysfunction-associated steatotic liver disease. A: Forest plot of the prevalence of metabolic dysfunction-associated steatohepatitis; B: Forest plot of the annual incidence of metabolic dysfunction-associated steatotic liver disease. CI: Confidence interval.

Figure 3 Subgroup analysis of the prevalence of metabolic dysfunction-associated steatotic liver disease according to age. MASLD: Metabolic dysfunction-associated steatotic liver disease; CI: Confidence interval.

Figure 4 The metabolic dysfunction-associated steatotic liver disease prevalence map in China. A: Metabolic dysfunction-associated steatotic liver disease prevalence by region; B: Metabolic dysfunction-associated steatotic liver disease prevalence by province. MASLD: Metabolic dysfunction-associated steatotic liver disease; CI: Confidence interval.

Figure 5 Subgroup analysis of the prevalence of metabolic dysfunction-associated steatotic liver disease by study period. MASLD: Metabolic dysfunction-associated steatotic liver disease; CI: Confidence interval.

Figure 6 Prevalence of extrahepatic comorbidities of metabolic dysfunction-associated steatotic liver disease. MASLD: Metabolic dysfunction-associated steatotic liver disease; CI: Confidence interval.